Asset
HALOFUGINONE
Processa Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01978366 | phase2 | terminated | 2013-10-01 | 2016-04-30 | Processa Pharmaceuticals | Open Label Extension Study of HT-100 in Patients With DMD |
| NCT01847573 | phase1_2 | terminated | 2013-05-01 | 2016-03-30 | Processa Pharmaceuticals | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy |
FDA applications (0)
This company has no applications containing this asset.